## Edgar Filing: Dekker Martin - Form 4

Dekker Ma Form 4	rtin								
November	23, 2018								
FOR	<b>M</b> 4		CECU			CHANGI			PPROVAL
	UNITED	) STATES		RITIES A shington,			E COMMISSIO	N OMB Number:	3235-0287
if no lo	this box		~~~					Expires:	January 31, 2005
subject Section Form 4 Form 5	to SIAIE		F CHANGES IN BENEFICIAL OWNERSHIP C SECURITIES					Estimated burden hou response	average urs per
obligat may co	ions Section 17	(a) of the P	ublic U	Itility Hol	ding Cor		nge Act of 1934, a of 1935 or Secti 1940		
(Print or Type	e Responses)								
1. Name and Address of Reporting Person <u>*</u> Dekker Martin			2. Issuer Name <b>and</b> Ticker or Trading Symbol Bellerophon Therapeutics, Inc.			5. Relationship of Reporting Person(s) to Issuer			
			[BLPH	•	rapeutie	5, me.	(Cho	eck all applicabl	e)
(Last) (First) (Middle)			3. Date of Earliest Transaction (Month/Day/Year)			Director 10% Owner X Officer (give title Other (specify below) below)			
	LEROPHON EUTICS, INC., 18		11/20/2	2018			below) VP of E	Engineering & N	lanuf
LIBERTY 302	CORNER ROAI	D, SUITE							
				If Amendment, Date Original led(Month/Day/Year)			6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person		
WARREN	I, NJ 07059						Form filed by Person		
(City)	(State)	(Zip)	Tab	ole I - Non-I	Derivative	Securities A	Acquired, Disposed	of, or Beneficia	lly Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	e 2A. Deeme Execution I any (Month/Day	Date, if	3. Transactio Code (Instr. 8)	4. Securit nAcquired Disposed (Instr. 3, 4	(A) or of (D)	5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Indirect
				Code V	Amount	<ul><li>(A)</li><li>or</li><li>(D) Price</li></ul>	Reported Transaction(s) (Instr. 3 and 4)		
Reminder: R	eport on a separate lin	ne for each cla	ss of sec	urities benef	ficially ow	ned directly	or indirectly.		
					inform	nation con	spond to the colle tained in this forn ond unless the fo	n are not	SEC 1474 (9-02)

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

number.

displays a currently valid OMB control

## Edgar Filing: Dekker Martin - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D (Instr. 3, 4, and 5)		Date	7. Title and A Underlying S (Instr. 3 and	Securities
				Code V	(A) (D	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	\$ 0.91	11/20/2018		A	137,500	<u>(1)</u>	11/20/2028	Common Stock	137,500

## **Reporting Owners**

<b>Reporting Owner Name / Address</b>	Relationships				
	Director	10% Owner	Officer	Other	
Dekker Martin C/O BELLEROPHON THERAPEUTICS, INC. 184 LIBERTY CORNER ROAD, SUITE 302 WARREN, NJ 07059			VP of Engineering & Manuf		
Signatures					

/s/ Martin	11/20/2018		
Dekker			
<u>**Signature of</u>	Date		

Reporting Person

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This option was granted on November 20, 2018. This option vests in quarterly installments over a four-years period from the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.